Get the Stockscreener App
10.42
1.56%
0.16
Pre-market:
9.12
-1.30
-12.48%
Cullinan Therapeutics Inc stock is traded at $10.42, with a volume of 342.36K.
It is up +1.56% in the last 24 hours and down -10.17% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
See More
Previous Close:
$10.26
Open:
$10.39
24h Volume:
342.36K
Relative Volume:
0.67
Market Cap:
$606.73M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.8238
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+4.10%
1M Performance:
-10.17%
6M Performance:
-43.03%
1Y Performance:
-9.47%
1-Day Range:
$10.26
$10.52
1-Week Range:
$9.83
$10.52
52-Week Range:
$9.5005
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
10.42 | 606.73M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week LowHere's What Happened - MarketBeat
Harbor Capital Advisors Inc. Purchases 9,385 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Should You Sell? - MarketBeat
Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics' chief scientific officer sells shares worth $50,040 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap UpWhat's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat
Don't Ignore The Insider Selling In Cullinan Therapeutics - Simply Wall St
Financial Comparison: Genfit (NASDAQ:GNFT) vs. Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Geode Capital Management LLC Acquires 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Geode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics CEO sells shares worth $99,708 - Investing.com India
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Sells 8,400 Shares of Stock - MarketBeat
Cullinan Therapeutics CEO sells shares worth $99,708 By Investing.com - Investing.com South Africa
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.9%Should You Sell? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of “Buy” by Analysts - Defense World
Barclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.6% Higher – Here’s Why - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street Corp - Defense World
State Street Corp Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat
Cullinan Therapeutics' chief medical officer sells $52,851 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief medical officer sells $52,851 in stock - Investing.com
Cullinan Therapeutics chief scientific officer sells $53,547 in stock - Investing.com
Cullinan therapeutics chief legal officer sells $39,729 in stock - Investing.com India
Cullinan Therapeutics chief scientific officer sells $53,547 in stock By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6%What's Next? - MarketBeat
Fmr LLC Purchases 19,681 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Franklin Resources Inc. Sells 252,868 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 4%Here's Why - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.19 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 3,489 Shares of Stock - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Charles Schwab Investment Management Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Purchased by RTW Investments LP - MarketBeat
Patient Square Capital LP Acquires New Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Holocene Advisors LP - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Walleye Capital LLC - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Braidwell LP - MarketBeat
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $31.67 - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $31.67 Average Target Price from Brokerages - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):